Search

Your search keyword '"Koyama, Kumiko"' showing total 180 results
Start Over Author "Koyama, Kumiko"
180 results on '"Koyama, Kumiko"'

4. Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy.

Author

Satake, Tomoyuki, Morizane, Chigusa, Okada, Mao, Nishioka, Mariko, Hiraoka, Nobuyoshi, Nara, Satoshi, Kakegawa, Tomoya, Kobayashi, Maki, Koyama, Kumiko, Esaki, Minoru, and Okusaka, Takuji

Abstract

Background: Although activation of human epidermal growth factor receptor 3 (HER3) is linked to resistance to targeted therapies in several cancer types, the HER3 expression profile during pancreatic cancer treatment remains unknown. Aims: We evaluated the HER3 expression status after chemotherapy for pancreatic cancer and its association with clinicopathological features and clinical outcomes. Materials & Methods: We included patients with pancreatic cancer who underwent chemotherapy and whose post‐treatment archival tissue specimens were collected. HER3 expression was retrospectively assessed by immunohistochemistry scoring (0, 1+, 2+, and 3+) of the membranous staining intensity. Results: HER3 expression after chemotherapy was evaluated in 41 patients, with matched‐pair analysis in five patients before and after chemotherapy. HER3 expression was observed in most of the patients after chemotherapy, demonstrating IHC scores of ≥ 1+ and ≥ 2+ in 40 (98%) and 26 (63%) of 41 patients, respectively. Of the 38 patients with adenocarcinoma, the median overall survival in the HER3 (2+/3+) and HER3 (0/1+) groups was 21.0 and 17.1 months, respectively. The comparison of HER3 expression before and after chemotherapy performed in five cases revealed that scores changed from 2+/3+ to 0/1+ in one case, 0/1+ to 2+/3+ in another case, and remained at 2+/3+ in three cases. Cancer genome profiling tests in eight cases found no HER3 amplification or mutation, and seven of these cases had adenocarcinomas with KRAS and TP53 mutations. Conclusion: A high prevalence of HER3 expression was observed in pancreatic cancer patients after chemotherapy. Our findings indicate that HER3 is a potential therapeutic target for pancreatic cancer, deserving further clinical investigation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. The First Case of a Cat Infected with Burkholderia pseudomultivorans , a Member of the Burkholderia cepacia Complex.

Author

Fujii, Yuji, Suwa, Akihisa, Tsuyuki, Yuzo, Koyama, Kumiko, Nio-Kobayashi, Junko, and Yoshii, Kentaro

Subjects
BURKHOLDERIA cepacia, OPPORTUNISTIC infections, VETERINARY medicine, SEPTIC shock, PETS
Abstract

Simple Summary: The Burkholderia cepacia complex (Bcc) is a group of more than 20 closely related species associated with opportunistic infections. In this report, we describe a species identification of a Bcc strain detected from a cat with sepsis. A 9-year-old, FIV-positive, mixed-breed cat died during the immunosuppressive therapy. In the bone marrow specimen collected postmortem, numerous short bacilli were observed. Bacteriological examination and genetic analysis revealed that the bacterial species isolated from the cat was B. pseudomultivorans, a member of Bcc. This is the first report of infection with B. pseudomultivorans in companion animals. The findings of this study indicate that further investigations of Bcc infections should be performed in veterinary medicine. The Burkholderia cepacia complex (Bcc) is a group of bacteria with similar biological properties which are an important cause of opportunistic infections. Identification of the Bcc species is important to understand clinical outcomes in human patients. However, there are few studies of Bcc species infecting companion animals such as cats. This report shows for the first time an infection with B. pseudomultivorans, a member of Bcc, in veterinary medicine. A 9-year-old, FIV-positive, mixed-breed cat was subjected to immunosuppressive therapy, developed septic shock, and died. In the bone marrow specimen collected postmortem, numerous short bacilli—some of which were phagocytosed by leukocytes—were observed. By bacteriological examination, the Bcc-like bacteria were isolated from the bone marrow sample. Genetic analysis showed that the recA gene sequence detected from the present case exhibited the highest homology (98–100%) to that of B. pseudomultivorans. Based on these examinations, the present case was diagnosed as B. pseudomultivorans infection. The findings of this study highlight the need for investigation of the Bcc species in veterinary practice to help in treatment decisions and the prognostic evaluation of Bcc infections. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial

Author

Krop, Ian E., primary, Masuda, Norikazu, additional, Mukohara, Toru, additional, Takahashi, Shunji, additional, Nakayama, Takahiro, additional, Inoue, Kenichi, additional, Iwata, Hiroji, additional, Yamamoto, Yutaka, additional, Alvarez, Ricardo H., additional, Toyama, Tatsuya, additional, Takahashi, Masato, additional, Osaki, Akihiko, additional, Saji, Shigehira, additional, Sagara, Yasuaki, additional, O'Shaughnessy, Joyce, additional, Ohwada, Shoichi, additional, Koyama, Kumiko, additional, Inoue, Tatsuya, additional, Li, Li, additional, Patel, Parul, additional, Mostillo, Joseph, additional, Tanaka, Yoshimi, additional, Sternberg, David W., additional, Sellami, Dalila, additional, and Yonemori, Kan, additional

Published
2023
Full Text
View/download PDF

7. Abstract LB042: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd)in tamoxifen-resistant ER+ breast cancer cells by inducing DNA damage and apoptosis

Author

Xie, Xuemei, primary, Lee, Jangsoon, additional, Fuson, Jon A., additional, Liu, Huey, additional, Gi, Young J., additional, Poullikkas, Thanasis, additional, Fan, Pang-Dian, additional, Koyama, Kumiko, additional, Tripathy, Debu, additional, and Ueno, Naoto T., additional

Published
2023
Full Text
View/download PDF

11. Supplementary Table 1 from A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

Author

Hashimoto, Yuuri, primary, Koyama, Kumiko, primary, Kamai, Yasuki, primary, Hirotani, Kenji, primary, Ogitani, Yusuke, primary, Zembutsu, Akiko, primary, Abe, Manabu, primary, Kaneda, Yuki, primary, Maeda, Naoyuki, primary, Shiose, Yoshinobu, primary, Iguchi, Takuma, primary, Ishizaka, Tomomichi, primary, Karibe, Tsuyoshi, primary, Hayakawa, Ichiro, primary, Morita, Koji, primary, Nakada, Takashi, primary, Nomura, Taisei, primary, Wakita, Kenichi, primary, Kagari, Takashi, primary, Abe, Yuki, primary, Murakami, Masato, primary, Ueno, Suguru, primary, and Agatsuma, Toshinori, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 1 from A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

Author

Hashimoto, Yuuri, primary, Koyama, Kumiko, primary, Kamai, Yasuki, primary, Hirotani, Kenji, primary, Ogitani, Yusuke, primary, Zembutsu, Akiko, primary, Abe, Manabu, primary, Kaneda, Yuki, primary, Maeda, Naoyuki, primary, Shiose, Yoshinobu, primary, Iguchi, Takuma, primary, Ishizaka, Tomomichi, primary, Karibe, Tsuyoshi, primary, Hayakawa, Ichiro, primary, Morita, Koji, primary, Nakada, Takashi, primary, Nomura, Taisei, primary, Wakita, Kenichi, primary, Kagari, Takashi, primary, Abe, Yuki, primary, Murakami, Masato, primary, Ueno, Suguru, primary, and Agatsuma, Toshinori, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 3 from A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

Author

Hashimoto, Yuuri, primary, Koyama, Kumiko, primary, Kamai, Yasuki, primary, Hirotani, Kenji, primary, Ogitani, Yusuke, primary, Zembutsu, Akiko, primary, Abe, Manabu, primary, Kaneda, Yuki, primary, Maeda, Naoyuki, primary, Shiose, Yoshinobu, primary, Iguchi, Takuma, primary, Ishizaka, Tomomichi, primary, Karibe, Tsuyoshi, primary, Hayakawa, Ichiro, primary, Morita, Koji, primary, Nakada, Takashi, primary, Nomura, Taisei, primary, Wakita, Kenichi, primary, Kagari, Takashi, primary, Abe, Yuki, primary, Murakami, Masato, primary, Ueno, Suguru, primary, and Agatsuma, Toshinori, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 2 from A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

Author

Hashimoto, Yuuri, primary, Koyama, Kumiko, primary, Kamai, Yasuki, primary, Hirotani, Kenji, primary, Ogitani, Yusuke, primary, Zembutsu, Akiko, primary, Abe, Manabu, primary, Kaneda, Yuki, primary, Maeda, Naoyuki, primary, Shiose, Yoshinobu, primary, Iguchi, Takuma, primary, Ishizaka, Tomomichi, primary, Karibe, Tsuyoshi, primary, Hayakawa, Ichiro, primary, Morita, Koji, primary, Nakada, Takashi, primary, Nomura, Taisei, primary, Wakita, Kenichi, primary, Kagari, Takashi, primary, Abe, Yuki, primary, Murakami, Masato, primary, Ueno, Suguru, primary, and Agatsuma, Toshinori, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Materials and Methods from A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

Author

Hashimoto, Yuuri, primary, Koyama, Kumiko, primary, Kamai, Yasuki, primary, Hirotani, Kenji, primary, Ogitani, Yusuke, primary, Zembutsu, Akiko, primary, Abe, Manabu, primary, Kaneda, Yuki, primary, Maeda, Naoyuki, primary, Shiose, Yoshinobu, primary, Iguchi, Takuma, primary, Ishizaka, Tomomichi, primary, Karibe, Tsuyoshi, primary, Hayakawa, Ichiro, primary, Morita, Koji, primary, Nakada, Takashi, primary, Nomura, Taisei, primary, Wakita, Kenichi, primary, Kagari, Takashi, primary, Abe, Yuki, primary, Murakami, Masato, primary, Ueno, Suguru, primary, and Agatsuma, Toshinori, primary

Published
2023
Full Text
View/download PDF

16. Additional file 7 of Changes in HER3 expression profiles between primary and recurrent gynecological cancers

Author

Kojima, Yuki, Sudo, Kazuki, Yoshida, Hiroshi, Yazaki, Shu, Tokura, Momoko, Mizoguchi, Chiharu, Okuma, Hitomi S., Kita, Shosuke, Yamamoto, Kasumi, Nishikawa, Tadaaki, Noguchi, Emi, Shimoi, Tatsunori, Tanase, Yasuhito, Uno, Masaya, Ishikawa, Mitsuya, Kato, Tomoyasu, Koyama, Kumiko, Kobayashi, Maki, Kakegawa, Tomoya, Fujiwara, Yasuhiro, and Yonemori, Kan

Abstract

Additional file 7. Supplemental Figs. 1–3. Supplemental Fig. 1. Histological findings of HER3 expression status. Surgical specimen of ovarian cancer (A); biopsy specimen of ovarian cancer (B); endometrial cancer (C); cervical cancer (D). Supplemental Fig. 2. Changes in HER3 expression between primary and recurrent status. Proportion of HER3-high at primary and recurrent status in ovarian cancer; high-grade serous carcinomas vs. others (A), platinum-sensitive recurrence vs. resistant recurrence (B), localized relapse vs. distant metastases (C), and one type of prior therapy vs. two or more (D). Proportion of HER3-high at primary and recurrent status in endometrial cancer; low-grade vs. high-grade (E), localized relapse vs. distant metastases (F), and non-chemotherapy vs. prior chemotherapy (G). Supplemental Fig. 3. Kaplan‒Meier survival analysis of overall survival, including changed HER3 status at recurrence. (A) ovarian cancer and (B) endometrial cancer in patients with HER3-decreased vs. patients with HER3-no chang vs. patients with HER3-increased at recurrence.

Published
2023
Full Text
View/download PDF

17. Additional file 4 of Changes in HER3 expression profiles between primary and recurrent gynecological cancers

Author

Kojima, Yuki, Sudo, Kazuki, Yoshida, Hiroshi, Yazaki, Shu, Tokura, Momoko, Mizoguchi, Chiharu, Okuma, Hitomi S., Kita, Shosuke, Yamamoto, Kasumi, Nishikawa, Tadaaki, Noguchi, Emi, Shimoi, Tatsunori, Tanase, Yasuhito, Uno, Masaya, Ishikawa, Mitsuya, Kato, Tomoyasu, Koyama, Kumiko, Kobayashi, Maki, Kakegawa, Tomoya, Fujiwara, Yasuhiro, and Yonemori, Kan

Abstract

Additional file 4: Table S4. HER3 expression in ovarian cancer at initial diagnosis

Published
2023
Full Text
View/download PDF

18. Additional file 2 of Changes in HER3 expression profiles between primary and recurrent gynecological cancers

Author

Kojima, Yuki, Sudo, Kazuki, Yoshida, Hiroshi, Yazaki, Shu, Tokura, Momoko, Mizoguchi, Chiharu, Okuma, Hitomi S., Kita, Shosuke, Yamamoto, Kasumi, Nishikawa, Tadaaki, Noguchi, Emi, Shimoi, Tatsunori, Tanase, Yasuhito, Uno, Masaya, Ishikawa, Mitsuya, Kato, Tomoyasu, Koyama, Kumiko, Kobayashi, Maki, Kakegawa, Tomoya, Fujiwara, Yasuhiro, and Yonemori, Kan

Abstract

Additional file 2: Table S2. Patient characteristics of endometrial cancer

Published
2023
Full Text
View/download PDF

19. Additional file 3 of Changes in HER3 expression profiles between primary and recurrent gynecological cancers

Author

Kojima, Yuki, Sudo, Kazuki, Yoshida, Hiroshi, Yazaki, Shu, Tokura, Momoko, Mizoguchi, Chiharu, Okuma, Hitomi S., Kita, Shosuke, Yamamoto, Kasumi, Nishikawa, Tadaaki, Noguchi, Emi, Shimoi, Tatsunori, Tanase, Yasuhito, Uno, Masaya, Ishikawa, Mitsuya, Kato, Tomoyasu, Koyama, Kumiko, Kobayashi, Maki, Kakegawa, Tomoya, Fujiwara, Yasuhiro, and Yonemori, Kan

Abstract

Additional file 3: Table S3. Patient characteristics of cervical cancer

Published
2023
Full Text
View/download PDF

20. Additional file 6 of Changes in HER3 expression profiles between primary and recurrent gynecological cancers

Author

Kojima, Yuki, Sudo, Kazuki, Yoshida, Hiroshi, Yazaki, Shu, Tokura, Momoko, Mizoguchi, Chiharu, Okuma, Hitomi S., Kita, Shosuke, Yamamoto, Kasumi, Nishikawa, Tadaaki, Noguchi, Emi, Shimoi, Tatsunori, Tanase, Yasuhito, Uno, Masaya, Ishikawa, Mitsuya, Kato, Tomoyasu, Koyama, Kumiko, Kobayashi, Maki, Kakegawa, Tomoya, Fujiwara, Yasuhiro, and Yonemori, Kan

Abstract

Additional file 6: Table S6. HER3 expression in cervical cancer at initial diagnosis

Published
2023
Full Text
View/download PDF

23. Changes in HER3 expression profiles between primary and recurrent gynecological cancers

Author

Kojima, Yuki, primary, Sudo, Kazuki, additional, Yoshida, Hiroshi, additional, Yazaki, Shu, additional, Tokura, Momoko, additional, Mizoguchi, Chiharu, additional, Okuma, Hitomi S, additional, Kita, Shosuke, additional, Yamamoto, Kasumi, additional, Nishikawa, Tadaaki, additional, Noguchi, Emi, additional, Shimoi, Tatsunori, additional, Tanase, Yasuhito, additional, Uno, Masaya, additional, Ishikawa, Mitsuya, additional, Kato, Tomoyasu, additional, Koyama, Kumiko, additional, Kobayashi, Maki, additional, Kakegawa, Tomoya, additional, Fujiwara, Yasuhiro, additional, and Yonemori, Kan, additional

Published
2022
Full Text
View/download PDF

24. Pan-cancer gene expression analysis of tissue microarray using EdgeSeq oncology biomarker panel and a cross-comparison with HER2 and HER3 immunohistochemical analysis

Author

Inaki, Koichiro, primary, Shibutani, Tomoko, additional, Maeda, Naoyuki, additional, Eppenberger-Castori, Serenella, additional, Nicolet, Stefan, additional, Kaneda, Yuki, additional, Koyama, Kumiko, additional, Qiu, Yang, additional, Wakita, Kenichi, additional, and Murakami, Masato, additional

Published
2022
Full Text
View/download PDF

25. Abstract 5083: Changes in HER3 expression profiles between initial diagnosis and recurrence in gynecologic cancers

Author

Kojima, Yuki, primary, Sudo, Kazuki, additional, Yoshida, Hiroshi, additional, Yazaki, Shu, additional, Tokura, Momoko, additional, Kita, Shosuke, additional, Yamamoto, Kasumi, additional, Mizoguchi, Chiharu, additional, Okuma, Hitomi S, additional, Nishikawa, Tadaaki, additional, Noguchi, Emi, additional, Shimoi, Tatsunori, additional, Tanase, Yasuhito, additional, Uno, Masaya, additional, Ishikawa, Mitsuya, additional, Kato, Tomoyasu, additional, Koyama, Kumiko, additional, Kobayashi, Maki, additional, Kakegawa, Tomoya, additional, Fujiwara, Yasuhiro, additional, and Yonemori, Kan, additional

Published
2022
Full Text
View/download PDF

27. HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target.

Author

Bent, Alisha Heather, primary, Maru, Dipen M., additional, Vauthey, Jean-Nicolas, additional, Dasari, Arvind, additional, Johnson, Benny, additional, Kee, Bryan K., additional, Parseghian, Christine Megerdichian, additional, Menter, David, additional, Overman, Michael J., additional, Morris, Van K., additional, Fan, Pang-Dian, additional, Koyama, Kumiko, additional, Maeda, Naoyuki, additional, Kopetz, Scott, additional, and Raghav, Kanwal Pratap Singh, additional

Published
2022
Full Text
View/download PDF

28. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).

Author

Krop, Ian E., primary, Masuda, Norikazu, additional, Mukohara, Toru, additional, Takahashi, Shunji, additional, Nakayama, Takahiro, additional, Inoue, Kenichi, additional, Iwata, Hiroji, additional, Toyama, Tatsuya, additional, Yamamoto, Yutaka, additional, Hansra, Damien Mikael, additional, Takahashi, Masato, additional, Osaki, Akihiko, additional, Koyama, Kumiko, additional, Inoue, Tatsuya, additional, Yonekura, Takatoshi, additional, Mostillo, Joseph, additional, Ohwada, Shoichi, additional, Tanaka, Yoshimi, additional, Sternberg, David W., additional, and Yonemori, Kan, additional

Published
2022
Full Text
View/download PDF

30. Abstract P5-13-14: Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)

Author

Òdena, Andreu, primary, Monserrat, Laia, additional, Brasó-Maristany, Fara, additional, Guzmán, Marta, additional, Grueso, Judit, additional, Rodríguez, Olga, additional, Scaltriti, Maurizio, additional, Chandarlapaty, Sarat, additional, Qiu, Yang, additional, Koyama, Kumiko, additional, Oliveira, Mafalda, additional, Prat, Aleix, additional, and Serra, Violeta, additional

Published
2022
Full Text
View/download PDF

31. Quantitative analysis of drug distribution in heterogeneous tissues using dual‐stacking capillary electrophoresis–mass spectrometry.

Author

Koganemaru, Shigehiro, Kawai, Takayuki, Fuchigami, Hirobumi, Maeda, Naoyuki, Koyama, Kumiko, Kuboki, Yasutoshi, Mukohara, Toru, Doi, Toshihiko, and Yasunaga, Masahiro

Subjects
DRUG discovery, CAPILLARY electrophoresis, ANTIBODY-drug conjugates, SPECTROMETRY, QUANTITATIVE research, CAPILLARIES
Abstract

Background and Purpose: Intratumour heterogeneity frequently leads to drug resistance, which is a major issue in drug discovery. Drug distribution is one of the key factors for elucidating the resistance mechanism; however, quantitative and regional drug measurement is challenging. Here, we developed a novel ultra‐sensitive analytical method and applied it to HER3‐targeting antibody–drug conjugate patritumab deruxtecan (HER3‐DXd), aiming to explore its payload (DXd) distribution within heterogeneous tissues. Experimental Approach: The developed analytical method is named LDMS‐CE‐MS, a capillary electrophoresis‐mass spectrometry (CE‐MS) coupled with a novel sample preconcentration/separation method called "large‐volume dual‐sample stacking by micelle collapse and sweeping (LDMS)". First, the analytical performance of LDMS‐CE‐MS for DXd detection was evaluated. Subsequently, we evaluated the bystander effect of HER3‐DXd, where tumour tissues were excised from xenograft models and clinical specimens after administration of HER3‐DXd. HER3‐high expression, adjacent, and HER3‐low expression regions were then sampled by laser microdissection to quantify the released DXd. Key Results: LDMS concentrated DXd by 1000‐fold and separated it from the hydrophilic bio‐matrix through continuous capture and release by the charged micelles, allowing quantification at sub‐attomole‐level. DXd concentrations decreased in the order of antigen‐high expression > adjacent > antigen‐low expression regions in the tumour xenograft model, whereas in clinical specimens, adjacent and antigen‐high expression regions had approximately the same concentration. These distributions represent a bystander effect. Conclusions and Implications: Our LDMS‐CE‐MS successfully visualized the attomole‐level drug distributions in heterogeneous clinical specimens. This new platform opens a new era of quantitative pharmacokinetic analysis, facilitating drug discovery and development. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Mutations of Chromosome 5q21 Genes in FAP and Colorectal Cancer Patients

Author

Nishisho, Isamu, Nakamura, Yusuke, Miyoshi, Yasuo, Miki, Yoshio, Ando, Hiroshi, Horii, Akira, Koyama, Kumiko, Utsunomiya, Joji, Baba, Shozo, Hedge, Philip, Markham, Alex, Krush, Anne J., Petersen, Gloria, Hamilton, Stanley R., Nilbert, Mef C., Levy, Daniel B., Bryan, Tracy M., Preisinger, Antonette C., Smith, Kelly J., Su, Li-Kuo, Kinzler, Kenneth W., and Vogelstein, Bert

Published
1991

35. Abstract 5880: Pan-cancer gene expression analysis of tissue microarray using EdgeSeq Oncology Biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis

Author

Inaki, Koichiro, primary, Maeda, Naoyuki, additional, Shibutani, Tomoko, additional, Eppenberger-Castori, Serenella, additional, Nicolet, Stefan, additional, Koyama, Kumiko, additional, Tanaka, Yui, additional, Kaneda, Yuki, additional, Wakita, Kenichi, additional, Shiose, Yoshinobu, additional, and Murakami, Masato, additional

Published
2020
Full Text
View/download PDF

42. A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

Author

Hashimoto, Yuuri, primary, Koyama, Kumiko, additional, Kamai, Yasuki, additional, Hirotani, Kenji, additional, Ogitani, Yusuke, additional, Zembutsu, Akiko, additional, Abe, Manabu, additional, Kaneda, Yuki, additional, Maeda, Naoyuki, additional, Shiose, Yoshinobu, additional, Iguchi, Takuma, additional, Ishizaka, Tomomichi, additional, Karibe, Tsuyoshi, additional, Hayakawa, Ichiro, additional, Morita, Koji, additional, Nakada, Takashi, additional, Nomura, Taisei, additional, Wakita, Kenichi, additional, Kagari, Takashi, additional, Abe, Yuki, additional, Murakami, Masato, additional, Ueno, Suguru, additional, and Agatsuma, Toshinori, additional

Published
2019
Full Text
View/download PDF

43. Abstract LB-264: Autophagy modulates intracellular dynamics of [fam-] trastuzumab deruxtecan (DS-8201a), a novel HER2 antibody-drug conjugate (HER2-ADC)

Author

Abe, Manabu, primary, Nagata, Motoko, additional, Koyama, Kumiko, additional, Yasuda, Satoru, additional, Hirata, Tsuyoshi, additional, Kuwahara, Yusuke, additional, Inaki, Koichiro, additional, Kasanuki, Naomi, additional, Minami, Megumi, additional, Hagihara, Katsunobu, additional, Wakita, Kenichi, additional, Slosberg, Eric, additional, and Murakami, Masato, additional

Published
2019
Full Text
View/download PDF

44. Abstract LB-275: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits its antitumor activity through increased payload intracellular delivery via highly efficient drug internalization

Author

Koyama, Kumiko, primary, Hashimoto, Yuuri, additional, Kamai, Yasuki, additional, Shiose, Yoshinobu, additional, Abe, Manabu, additional, Kaneda, Yuki, additional, Maeda, Naoyuki, additional, Hirotani, Kenji, additional, Ogitani, Yusuke, additional, Karibe, Tsuyoshi, additional, Kagari, Takashi, additional, Wakita, Kenichi, additional, Ueno, Suguru, additional, Agatsuma, Toshinori, additional, and Murakami, Masato, additional

Published
2019
Full Text
View/download PDF

46. Pharmacological properties of a novel PI3Kd inhibitor, DS-1515

Author

Wakita, Kenichi, primary, Koyama, Kumiko, additional, Nakayama, Shintaro, additional, Nishiya, Yumi, additional, Chopra, Puneet, additional, Seth, Mahesha, additional, Chabbra, Pooja, additional, Srivastava, Punit, additional, Kumar, Ankur, additional, Diwan, Manish, additional, Morimoto, Kiyoshi, additional, and Suzuki, Masakatsu, additional

Published
2018
Full Text
View/download PDF

48. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma

Author

Koul, Dimpy, primary, Wang, Shuzhen, additional, Wu, Shaofang, additional, Saito, Norihiko, additional, Zheng, Siyuan, additional, Gao, Feng, additional, Kaul, Isha, additional, Setoguchi, Masaki, additional, Nakayama, Kiyoshi, additional, Koyama, Kumiko, additional, Shiose, Yoshinobu, additional, Sulman, Erik P., additional, Hirota, Yasuhide, additional, and Yung, W. K. Alfred, additional

Published
2017
Full Text
View/download PDF

50. Strategy and clinical results of uterine fibroid embolization (UFE) for symptomatic uterine leiomyoma patients: analysis of over nine hundred cases

Author

Koyama, Kumiko

Subjects
Embolisation, Interventional vascular, Outcomes, Catheter arteriography
Abstract

Learning objectives Background Imaging findings OR Procedure details Conclusion References Personal Information, Learning objectives: The purpose of this exhibit are 1. To know indications of UFE correlating with clinical aspects 2. To learn patient select, technique and UFE results 3. To know strategy of UFE for expecting mothers 4. To understand effectiveness pre and post UFE MR...

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results